Tamoxifen Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Condition:   Breast Cancer, Early Breast Cancer Interventions:   Drug: Camizestrant;   Drug: Tamoxifen;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2023 Category: Research Source Type: clinical trials